Vaccine maker Moderna announced Wednesday that the first participants have received its modified Covid-19 vaccines, designed as potential boosters to address emerging virus variants.
As part of its Phase 2 study, 60 participants who were already vaccinated with Moderna’s original Covid-19 vaccine will be given a booster dose of the modified vaccines the company is testing.
Moderna’s Covid-19 vaccine is currently authorized for emergency use in the US. Though the vaccine was shown to provide protection against virus variants, it did show a six-fold decrease in the antibody response created against the B.1.351 variant, first identified in South Africa.
Moderna says it’s developing a strategy to address these emerging variants out of an abundance of caution.
In the trial, 20 people will receive a booster designed to address the B.1.351 variant and increase the response to emerging variants with similar mutations. Another 20 people will receive a larger dose of that same booster. The remaining 20 will receive a booster that combines the original vaccine with the B.1.351 booster to provide a broad immune response.
In parallel, Moderna says the National Institute of Allergy and Infectious Diseases (NIAD) will conduct another trial to assess the modified vaccines, both as boosters for those who received Moderna’s original Covid-19 vaccine and as a primary series for those who did not.
NIAD is expected to provide more information once it is given the all-clear from the US Food and Drug Administration to begin that trial.
COVID-19 - Latest - Google News
March 11, 2021 at 07:22AM
https://ift.tt/3rDKuLP
The latest on the coronavirus pandemic and vaccines: Live updates - cnn.com
COVID-19 - Latest - Google News
https://ift.tt/2SmHWC3
Bagikan Berita Ini
0 Response to "The latest on the coronavirus pandemic and vaccines: Live updates - cnn.com"
Post a Comment